Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats

Brain Research

Volumn 1073-1074, Issue 1, 2006, Pages 269-275

  Yoshida, Shelly T ^a,b   Baella, Shelley A ^a   Stuebner, Nancy M ^a   Crawford, Cynthia A ^a   McDougall, Sanders A ^a  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Butyrolactone (GBL); DOPA accumulation; Ontogeny; Partial D2 like receptor agonist; Reserpine; Terguride

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; AUTORECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DRUG VEHICLE; GAMMA BUTYROLACTONE; HALOPERIDOL; QUINPIROLE; RESERPINE; TERGURIDE; 3,4 DIHYDROXYPHENYLACETIC ACID; 3-HYDROXYBENZYLHYDRAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDRAZINE DERIVATIVE; LISURIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; FEEDBACK SYSTEM; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; COMPARATIVE STUDY; CORPUS STRIATUM; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; METABOLISM; NEWBORN; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA;

3,4-DIHYDROXYPHENYLACETIC ACID; 4-BUTYROLACTONE; ANIMALS; ANIMALS, NEWBORN; AUTORECEPTORS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; HALOPERIDOL; HYDRAZINES; LISURIDE; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RESERPINE;

EID: 33644951886     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2005.12.054     Document Type: Article

References (42)

1. S.L. Andersen, and R.A. Gazzara The ontogeny of apomorphine-induced alterations of neostriatal dopamine release: effects on spontaneous release J. Neurochem. 61 1993 2247 2255
2. S.L. Andersen, and R.A. Gazzara The development of D2 autoreceptor-mediated modulation of K(+)-evoked dopamine release in the neostriatum Dev. Brain Res. 78 1994 123 130
3. S.L. Andersen, N.L. Dumont, and M.H. Teicher Developmental differences in dopamine synthesis inhibition by (+/-)-7-OH-DPAT Naunyn-Schmiedebergs Arch. Pharmacol. 356 1997 173 181
4. J. Arnt Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers Eur. J. Pharmacol. 91 1983 273 278
5. J. Arnt, and J. Hyttel Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats J. Neural Transm. 60 1984 205 223
6. J. Arnt, and J. Hyttel Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques J. Neural Transm. 80 1990 33 50
7. R.J. Baldessarini, E.R. Marsh, and D. Huston-Lyons Effects of dopamine partial-agonist aminoergolines on dopamine metabolism in limbic and extrapyramidal regions of rat brain Biochem. Pharmacol. 47 1994 1917 1919
8. K.D. Burris, T.F. Molski, C. Xu, E. Ryan, K. Tottori, T. Kikuchi, F.D. Yocca, and P.B. Molinoff Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J. Pharmacol. Exp. Ther. 302 2002 381 389
9. A. Carlsson Dopamine receptor agonists: intrinsic activity vs. state of the receptor J. Neural Transm. 57 1983 309 315
10. D. Clark, S. Hjorth, and A. Carlsson Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity: I. Review of the evidence J. Neural Transm. 62 1985 1 52
11. D. Clark, S. Hjorth, and A. Carlsson Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity: II. Theoretical considerations J. Neural Transm. 62 1985 171 207
12. D. Clark, S. Hjorth, and A. Carlsson (+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis Eur. J. Pharmacol. 106 1985 185 189
13. D. Clark, L.J. Furmidge, N. Petry, Z.-Y. Tong, M. Ericsson, and D. Johnson Behavioural profile of partial D2 dopamine receptor agonists: 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy Psychopharmacology 105 1991 381 392
14. D. Clark, R.S. Salah, and M.P. Galloway Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine Synapse 8 1991 169 176
15. D.M. Coward, A.K. Dixon, S. Urwyler, T.G. White, A. Enz, M. Karobath, and G. Shearman Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912 J. Pharmacol. Exp. Ther. 252 1990 279 285
16. T.J. De Vries, A.H. Mulder, and A.N. Schoffelmeer Differential ontogeny of functional dopamine and muscarinic receptors mediating presynaptic inhibition of neurotransmitter release and postsynaptic regulation of adenylate cyclase activity in rat striatum Dev. Brain Res. 66 1992 91 96
17. B. Drukarch, and J.C. Stoof D-2 dopamine autoreceptor selective drugs: do they really exist? Life Sci. 47 1990 361 376
18. N.L. Dumont, S.L. Andersen, A.P. Thompson, and M.H. Teicher Transient dopamine synthesis modulation in prefrontal cortex: in vitro studies Dev. Brain Res. 150 2004 163 166
19. T. Hedner, and P. Lundborg Development of dopamine autoreceptors in the postnatal rat brain J. Neural Transm. 62 1985 53 63
20. S. Hjorth, A. Carlsson, D. Clark, K. Svensson, H. Wikstrom, D. Sanchez, P. Lindberg, U. Hacksell, L.E. Arvidsson, A. Johansson, and J.L.G. Nilsson Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP Psychopharmacology 81 1983 89 99
21. S. Hjorth, D. Clark, and A. Carlsson Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation Eur. J. Pharmacol. 152 1988 207 215
22. D. Hoyer, and H.W.G.M. Boddeke Partial agonists, full agonists: dilemmas of definition Trends Pharmacol. Sci. 14 1993 270 275
23. 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions J. Neural Transm. 68 1987 171 189
24. W. Kehr Transdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolism Eur. J. Pharmacol. 97 1984 111 119
25. W.C. Kohler, and G. Herbster Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease Neurology 37 1987 723 727
26. 2 autoreceptors in rats are behaviorally functional at 21 but not 10 days of age Psychopharmacology 114 1994 262 268
27. S.A. McDougall, R.M. Hernandez, C.M. Reichel, and C.M. Farley The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats Psychopharmacology 178 2005 431 439
28. E. Meller, E. Helmer-Matyjek, K. Bohmaker, C.H. Adler, A.J. Friedhoff, and M. Goldstein Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists Eur. J. Pharmacol. 123 1986 311 314
29. E. Meller, K. Bohmaker, Y. Namba, A.J. Friedhoff, and M. Goldstein Relationship between receptor occupancy and response at striatal autoreceptors Mol. Pharmacol. 31 1987 592 598
30. M.J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J.-A. Boutin, and A. Newman-Tancredi Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J. Pharmacol. Exp. Ther. 303 2002 791 804
31. C. Orsini, G.F. Koob, and L. Pulvirenti Dopamine partial agonist reverses amphetamine withdrawal in rats Neuropsychopharmacology 25 2001 789 792
32. L. Pulvirenti, and G.F. Koob Dopamine receptor agonists, partial agonists and psychostimulant addiction Trends Pharmacol. Sci. 15 1994 374 379
33. I.A. Shalaby, and L.P. Spear Psychopharmacological effects of low and high doses of apomorphine during ontogeny Eur. J. Pharmacol. 67 1980 451 459
34. I.A. Shalaby, P.S. Dendel, and L.P. Spear Differential functional ontogeny of dopamine presynaptic receptor regulation Brain Res. 227 1981 434 439
35. 2-like agonist on the cocaine-induced behavioral sensitization of preweanling rats Pharmacol. Biochem. Behav. 76 2003 27 34
36. S.K. Sobrian, B.L. Jones, S. Varghese, and R.R. Holson Behavioral response profiles following drug challenge with dopamine receptor subtype agonists and antagonists in developing rat Neurotoxicol. Teratol. 25 2003 311 328
37. K. Svensson, A. Ekman, M.F. Piercey, W.E. Hoffmann, J.T. Lum, and A. Carlsson Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study Naunyn-Schmiedebergs Arch. Pharmacol. 344 1991 263 274
38. K. Svensson, E. Eriksson, and A. Carlsson Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects Neuropharmacology 32 1993 1037 1045
39. M.H. Teicher, A.L. Gallitano, H.A. Gelbard, H.K. Evans, E.R. Marsh, R.G. Booth, and R.J. Baldessarini Dopamine D1 autoreceptor function: possible expression in developing rat prefrontal cortex and striatum Dev. Brain Res. 63 1991 229 235
40. 3H]terguride (transdihydrolisuride) in the rat striatum Eur. J. Pharmacol. 136 1987 97 101
41. H. Wachtel, and R. Dorow Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride Life Sci. 32 1983 421 432
42. J.R. Walters, and R.H. Roth Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors Naunyn-Schmiedebergs Arch. Pharmacol. 296 1976 5 14